Cabozantinib tablets

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Renal Cell Carcinoma

Drug Information

Target Indication

Renal Cell Carcinoma

Clinical Trial

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals

EMA3/21/2014

Cometriq

Treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.

Orphan

Drug Science

Mechanism of action & safety profile

Developer

EXEL

Exelixis, Inc.

Related Pipeline

Glioblastoma Multiforme

Non-Clear Cell Renal Cell Carcinoma

Colorectal Cancer

Head and Neck Squamous Cell Carcinoma

Solid Tumors

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts